5896-17-3 2-苄氧基苯甲醛

运输信息：常温运输。危险描述：非危险化学品，德国运输安全委员会（WGK Germany）分类为3。

主要用于化学合成领域。

化学合成

合成路线 1（1. 合成：5896-17-3）

产率：100% 合成条件：With potassium carbonate In acetonitrile for 5 h; Reflux 实验步骤：向搅拌的sal 1醛（8.7mL，81.8mmol）的乙腈（80mL）溶液中加入苄基溴（13.2mL，90.07mmol）和K₂CO₃（13.6g，98.3mmol），在室温下依次进行。将混合物加热至回流，搅拌5小时。冷却至室温，通过硅藻土过滤，用EtOAc稀释，用水洗涤，无水MgSO₄干燥。过滤并减压浓缩，得到17.4克（80-100％）产物。 参考文献：[1] Organic Letters, 2010, vol. 12, #8, p.1732-1735；[2] Journal of the American Chemical Society, 2012, vol.134, #27, p.11153-11160；[3] Journal of Medicinal Chemistry, 2015, vol.58, #7, p.3188-3208；[4] Patent: WO2015/88272, 2015, A1；[5] Bioorganic and Medicinal Chemistry, 1999, vol.7, #2, p.279-286；[6] Chemical Communications, 2015, vol.51, #32, p.7012-7014；[7] Bioorganic and Medicinal Chemistry, 2006, vol.14, #24, p.8386-8395；[8] Chemistry - A European Journal, 2013, vol.19, #14, p.4563-4569；[9] European Journal of Medicinal Chemistry, 2017, vol.130, p.286-307；[10] Patent: KR101747694, 2017, B1；[11] Bioorganic and Medicinal Chemistry Letters, 2013, vol.23, #15, p.4297-4302；[12] Chinese Journal of Chemistry, 2016, vol.34, #7, p.683-688；[13] Organic and Biomolecular Chemistry, 2018, vol.16, #17, p.3114-3120；[14] Patent: US2008/293666, 2008, A1；[15] Chemistry - A European Journal, 2011, vol.17, #9, p.2698-2703；[16] Advanced Synthesis and Catalysis, 2013, vol.355, #14-15, p.2900-2907；[17] Advanced Synthesis and Catalysis, 2012, vol.354, #11-12, p.2073-2078；[18] Advanced Synthesis and Catalysis, 2012, vol.354, #11-12, p.2073-2078；[19] Patent: US2013/261295, 2013, A1；[20] Synthetic Communications, 1999, vol.29, #13, p.2361-2364；[21] Chemical Communications, 2016, vol.52, #54, p.8467-8470；[22] European Journal of Medicinal Chemistry, 2010, vol.45, #9, p.3531-3540；[23] Organic Letters, 2009, vol.11, #14, p.2972-2975；[24] Tetrahedron, 2008, vol.64, #19, p.4162-4173；[25] Synthesis, 2009, #11, p.1886-1896；[26] Journal of Organic Chemistry, 1996, vol.61, #1, p.223-227；[27] Patent: WO2015/134998, 2015, A1；[28] Patent: CN107266413, 2017, A；[29] Journal of Organic Chemistry, 2016, vol.81, #21, p.10180-10192；[30] Synthesis, 1995, #9, p.1135-1141；[31] Bioorganic and Medicinal Chemistry Letters, 2013, vol.23, #20, p.5523-5527；[32] Angewandte Chemie - International Edition, 2016, vol.55, #8, p.2870-2874；[33] Angew. Chem., 2016, vol.128, #8, p.2920-2924；[34] Synthesis, 1989, #3, p.167-172；[35] Tetrahedron Asymmetry, 1997, vol.8, #4, p.591-598；[36] Journal of Medicinal Chemistry, 1998, vol.41, #22, p.4261-4272；[37] Journal of the American Chemical Society, 2007, vol.129, #40, p.12086-12087；[38] Patent: US4478834, 1984, A；[39] Bioorganic and Medicinal Chemistry Letters, 2006, vol.16, #11, p.2996-2999；[40] Patent: US2009/12103, 2009, A1；[41] Journal of Chemical Research, 2009, #5, p.302-305；[42] Patent: EP1400529, 2004, A1；[43] European Journal of Organic Chemistry, 2011, #11, p.2133-2141；[44] Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, vol.26, #5, p.643-648；[45] Bioorganic and Medicinal Chemistry Letters, 2013, vol.23, #24, p.6816-6821；[46] European Journal of Medicinal Chemistry, 2014, vol.73, p.177-186；[47] Synthetic Communications, 2014, vol.44, #2, p.251-258；[48] Tetrahedron, 2014, vol.70, #49, p.9449-9455；[49] Bioorganic and Medicinal Chemistry, 2015, vol.23, #24, p.7521-7528；[50] Chemistry - A European Journal, 2016, vol.22, #23, p.7959-7963；[51] Chemical and Pharmaceutical Bulletin, 2016, vol.64, #6, p.632-637；[52] European Journal of Medicinal Chemistry, 2017, vol.135, p.24-33；[53] Bioorganic and Medicinal Chemistry, 2018, vol.26, #12, p.3145-3157